Background
Differential effects of G-CSF and GM-CSF on neutrophils in Hematopoeitic growth factors are a group of glycoproteins vitro that regulate the proliferation and differentiation of hematopoietic precursor cells.
1-4 Granulocyte colony-stimulating factor G-CSF and GM-CSF are chemoattractants for neutrophils 34, 35 (G-CSF) and granulocyte-macrophage colony-stimulating facand could prime these cells for an enhanced respiratory burst tor (GM-CSF) are myeloid-predominant growth factors which activity after stimulation with several agents. 26, [36] [37] [38] [39] [40] Both cytohave been purified to homogeneity, and their genes have been kines enhanced the antibody-dependent cellular cytotoxicity cloned.
5-9 G-CSF is now widely used to overcome con-(ADCC), 26, [39] [40] [41] [42] [43] [44] 1). The chemotactic activity was reduced in G-CSF 54 and GMNeutrophils play an important role in first-line defense and CSF [55] [56] [57] pretreated neutrophils. In addition, G-CSF and GMit is generally accepted that the number of peripheral blood CSF could alter the expression of neutrophil surface proteins. neutrophils and the duration of neutropenia is closely related GM-CSF could rapidly upregulate the surface expression of to the risk of infection. 23 The functional capacity of neutrothe CD11b 26, 27, [45] [46] [47] 58, 59 and downregulate the LAM-1 phils is also of major clinical importance. This is dramatically expression 48, 59 while more conflicting results have been seen in patients with congenital or acquired functional phagoreported on the influence of G-CSF on these molcyte disorders showing a high susceptibility to infections. ecules 25, 27, 48, 59, 60 (see Table 1 ). The CD35 expression Several studies have shown that G-CSF and GM-CSF can increased after stimulation with GM-CSF, but not with Ginfluence the phenotype and function of mature neutrophils CSF. 27,61 GM-CSF was more potent in enhancing some neutroin vitro. [24] [25] [26] [27] However, the most important effect of these cytophil functions, eg priming for an enhanced respiratory burst kines in therapeutical dosages in vivo is to stimulate proliferactivity 62 and the signal transduction mechanisms required for ation and differentiation of hematopoietic precursors. Furtherpriming were different in G-CSF-and GM-CSF-stimulated more, high doses of systemically administered G-CSF and cells. 63 Apoptosis of mature neutrophils was delayed by G-GM-CSF may act on tissues other than the bone marrow, eg CSF 64, 65 and GM-CSF. 65, 66 endothelial cells 28 or induce secondary cytokine release 29, 30 It is important to stress that the functional in vitro and ex and might influence neutrophil phenotype and function vivo studies of neutrophils were primarily performed on cells indirectly. Therefore, assessment of neutrophil function ex in suspension. However, physiologic stimuli like fMLP and ILvivo is important to understand the in vivo effects of these 1 have a much higher potency to trigger the respiratory burst activity in neutrophils adherent to endothelium or artificial surfaces. 67 Furthermore, stimulation of adherent, but not suspended neutrophils with G-CSF or GM-CSF could directly induce the production of ROI. 68, 69 This ability of G-CSF to Neutrophils from healthy adults. b Cytokine-induced neutrophils from patients with cancer, healthy adults or in some studies from primates (see text). n, normal; ↓, decreased; ↑, increased; (), not significant; NR, not reported.
Effects of pharmacological doses of G-CSF and GM-CSF on
nance of neutrophil precursors were seen in the bone marrow after a treatment period of 28 days with G-CSF at a dose of neutrophils in vivo 10 g/kg.
84
The GM-CSF-induced leukocytosis which increased in magnitude after repeated administration was due White blood cell subsets and neutrophil kinetics to increased numbers of eosinophilic and neutrophilic granulocytes and monocytes. [85] [86] [87] Bone marrow cellularity and Administration of pharmacological doses of G-CSF and GM-CSF to humans or animals resulted in a triphasic response: [70] [71] [72] [73] [74] [75] [76] [77] (1) myeloid/erythroid ratios also increased during GM-CSF therapy. 76, 85 In patients with congenital, cyclic and chronic neuMarket neutropenia occurring approximately 5-60 min after injection (depending on the mode of administration); (2) Leutropenias, G-CSF treatment was more effective in increasing the ANC than treatment with GM-CSF.
11,15,31,32 kocytosis due to release of neutrophils (G-CSF, GM-CSF), eosinophils and monocytes (GM-CSF) from the bone marrow Kinetic studies in humans have demonstrated that the halflife of circulating G-CSF-induced neutrophils remained norbeginning after 3-4 h; (3) Proliferation and differentiation of hematopoietic precursors in the bone marrow.
mal at 8 h, whereas the production rate showed a 9.4-fold increase 75 ( Table 1) . The time required for neutrophil precurThe first decrease of the absolute neutrophil count (ANC) was most probably caused by an activation of neutrophils (Gsors to mature and appear in the circulation was shortened from 5 days to 1 day. 75 In contrast, after treatment with GM-CSF, GM-CSF) and monocytes (GM-CSF) resulting in enhanced adherence to endothelium. This effect was also CSF the neutrophil production rate increased by only 50% without shortening of the release time. 87 The half-life of GMobserved after administration of chemotactic factors to animals, eg IL-8 78 or fMLP. 79 Devereux and coworkers 80 could CSF-induced neutrophils in the peripheral blood rose from 8 to 48 h. 87 show that the transient leukopenia after GM-CSF administration was due to a sequestration of leukocytes within the An elevated number of immature neutrophils was found in the peripheral blood of G-CSF and GM-CSF-treated subjects lungs; however, this could not be shown for G-CSF. 75 Studies investigating bone marrow samples at 4 and 12 h after admin-('left shift') 83, 87 and neutrophils displayed an altered morphology with Dohle bodies, (toxic) granulation and vacuolizistration of G-CSF to rats have shown a decreased number of mature neutrophils in the marrow indicating that the neutroation 83, 88, 89 (see below). philia occurring in this time interval was caused by a release of neutrophils from the bone marrow. 74 The proliferative effect of G-CSF on granulopoiesis in a hamster model could be Adherence observed as early as 12 h after a single injection of 10 g/kg and resulted in a significant increase in bone marrow cellu-G-CSF 25, 90 and GM-CSF 45-48 enhanced the adherence of neutrophils in vitro. G-CSF treatment of patients with cancer and larity and the number of bone marrow progenitors. 81 Repeated treatment of humans and nonhuman primates severe congenital neutropenia resulted in an increased adherence of the induced neutrophils to plastic surfaces 70 (Tables with G-CSF resulted in a stimulation of myelopoiesis and a dose-dependent sustained neutrophilia. However, high doses 1 and 2). By administration of GM-CSF to nonhuman primates Yong et al 46 could provide histologic evidence for an of G-CSF (30-60 g/kg bodyweight) also increased the number of monocytes and lymphocytes in the peripheral enhanced neutrophil adherence to pulmonary endothelium during the initial transient leukopenia which was suggested blood. 21 ,82-84 Furthermore, hypercellularity and predomi- by radiolabeling studies in humans. 80 These findings of an PMN which did not appear to have a huge influence on the overall ability of these cells to reach sites of inflammation in enhanced neutrophil adherence in vivo are in good accordance with the increased adherence found in vitro (Table 1) vivo. The increased adherence and altered expression of adhesion molecules induced by G-CSF and GM-CSF in vivo and the altered expression of the integrin CD11b. They reflect the activation induced by G-CSF and GM-CSF and might conand in vitro are likely to contribute to the decrease in chemotactic activity. tribute to the decreased chemotactic activity of these neutrophils (see below).
Impaired chemotaxis prior to G-CSF:
In patients with myelodysplastic syndromes (MDS) neutrophil function is often Chemotaxis abnormal 101 (eg impaired chemotaxis and phagocytosis) and might contribute to the increased risk of infection. The preinSomewhat conflicting results were reported about the chemotactic motility of neutrophils induced by G-CSF and GM-CSF cubation of MDS neutrophils with G-CSF 102 and GM-CSF 103 could enhance some of the impaired functions (eg production ( Tables 1 and 2 ). In this context, it is important to separate the effects of these cytokines on neutrophils in patients with of reactive oxygen intermediates (ROI), but GM-CSF further impaired the chemotactic response. 103 Treatment of these impaired neutrophil function caused by the underlying disease itself and on neutrophils in patients with normal neutrophil patients with G-CSF resulted in an increased or unchanged neutrophil motility 104 whereas GM-CSF further decreased the function before treatment with G-CSF. chemotactic activity. 105 In some disorders severe neutropenia did not allow functional studies prior to cytokine therapy 14, 106 and therefore results obtained during treatment are difficult Normal chemotaxis prior to cytokine treatment:
Ex vivo studies investigating neutrophils from G-CSF-treated patients to interpret. This is true for G-CSF-induced neutrophils from patients with severe congenital neutropenia 107, 108 and glycowith cancer and healthy volunteers have shown a decreased migration 70, 72, [91] [92] [93] which was related to the dose of G-CSF in genosis type IB (GSD IB) 11,14,109 which have been described to show moderate to severe impairment of their chemotactic one study. 70 During continuous intravenous infusion of GM-CSF, a markedly reduced neutrophil motility was found in a response towards a variety of chemoattractants in vitro. Measurement of neutrophil chemotaxis in one patient with skin chamber assay. 94, 95 The latter finding was in good accordance with the in vitro activity of GM-CSF as a potent GSD IB before and during treatment with G-CSF suggested an enhancement to the normal range in vitro and an increased inhibitor of neutrophil chemotaxis. 55, 57 However, other studies showed no impairment of neutrophil migration in G-CSFinfiltration in the skin chamber assay in vivo. 13 Qualitative evaluation of migration in four patients with severe congenital and GM-CSF-treated subjects in vitro 82,96,97 and in vivo. 98 Factors that might be responsible for the variable results of neutroneutropenia by the Rebuck-window revealed monocytic and lymphocytic cell infiltration prior to treatment and neutrophils phil chemotaxis in vivo include the use of different chemotaxis assays, the dose of cytokine, its mode of administration at the site of abrasion during treatment with G-CSF.
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Conflicting results were also reported about chemotactic and the time interval between cytokine administration and blood collection. The ability of G-CSF-induced neutrophils to motility of G-CSF-induced neutrophils from patients with cyclic neutropenia which has been found to be decreased in enter the mucosal surfaces of the oral cavity was assessed by Lieschke et al 99 using a mouthrinse assay in patients after bone vitro, 110 but to be normal in an in vivo assay. 16 Neutrophils assessed during G-CSF treatment in one patient with chronic marrow transplantation. The relationship between the ANC and the number of neutrophils recoverable from the oral cavneutropenia showed normal accumulation in a skin chamber assay. 17 ity was not altered by G-CSF treatment suggesting that G-CSFinduced neutrophils were able to leave the circulation and Taken together, the pronounced decrease of chemotactic activity in G-CSF-treated patients with impaired neutrophil enter tissue. The transfusion of radiolabelled leukocytes to a neutropenic patient with an invasive skin infection during function in in vitro tests suggests that G-CSF could not completely restore the functional defects. The increased neutrophil GM-CSF and pentoxifyllin treatment showed that these cells were able to localize to the site of infection. 100 counts during G-CSF treatment in some patients could explain the enhanced accumulation in skin window assays in vivo. Taken together the studies clearly indicate some decrease in the chemotactic motility of G-CSF-and GM-CSF-induced However, the evaluation of chemotaxis by different methods and the paucity of studies comparing chemotaxis before and PMA. 106,108,126 Another study described the O 2 -release after PMA stimulation to be impaired in a subgroup of G-CSFduring cytokine treatment limit these conclusions. Neutrophils constitutively express low affinity receptors for resulted in a grossly normal bacterial killing capacity of neumultimeric IgG ((Fc␥RII and Fc␥RIII) which mediate binding and trophils, whereas an enhanced neutrophil bactericidal activity lysis of target cells coated with IgG (ADCC) as well as binding was found in G-CSF-treated cancer patients. 115 The killing of and phagocytosis of immune complexes. 133 G-CSF could E. coli by neutrophils increased when GM-CSF was given to enhance ADCC of neutrophils from healthy donors, 40- (Tables 1 and 2 ). An enhanced ADCC was also found after exposure of neutrophils from healthy volunteers to Although G-CSF or GM-CSF alone were not able to initiate a GM-CSF in vitro 26, 39, 40, [42] [43] [44] and patients infected with HIV in respiratory burst in native neutrophils, preincubation with vitro and in vivo. 114 these cytokines 'primed' the cell for an enhanced superoxide The increased cytotoxicity of G-CSF-induced neutrophils anion production after stimulation with physiological stimuli, has been shown to be mediated by the induction of the Fc␥RI eg the chemotactic peptide fMLP. 25, 26, [36] [37] [38] [39] [40] 62 This effect was in cancer patients 131 and in healthy volunteers 71 and could be also observed after administration of G-CSF and GM-CSF to inhibited by antibodies blocking the binding site of the Fc␥RI. patients with cancer 83, [116] [117] [118] [119] [120] [121] and to healthy volunteers 122 However, the in vitro incubation of neutrophils with G-CSF (Table 1) . Neutrophils from patients with myelodysplastic syndid not induce Fc␥RI expression 27 and the enhanced ADCC dromes with impaired ROI production showed an enhancecould be inhibited by antibodies blocking the function of ment of respiratory burst activity after exposure to G-CSF or Fc␥RII. 44 Although the mechanisms of G-CSF-enhanced neu-GM-CSF in vitro 102, 103, 123, 124 and in vivo. 105, 124 Similar in vitro trophil cytotoxicity are not yet clear, they appear to be inderesults have been reported for G-CSF-induced neutrophils in pendent of oxidative metabolism. This could be demonstrated patients undergoing allogeneic or autologous BMT.
49, 113 The in neutrophils from patients with chronic granulomatous disadministration of GM-CSF after BMT could correct the defecease who have a severely impaired ability to produce ROI.
42
tive ROI production in some patients. 125 McCawley et al 109 Therefore, priming for an enhanced respiratory burst activity reported an improvement of the impaired neutrophil ROI procannot explain the G-CSF-induced enhanced cytotoxicity. duction from patients with GSD IB to normal levels after 4
In summary, G-CSF, but not GM-CSF induced the months of treatment with G-CSF. However, other authors expression of the Fc␥RI on neutrophils in vivo. Furthermore, found some impairment of the neutrophil ROI production G-CSF and GM-CSF were able to enhance the ADCC of neufrom these patients even during G-CSF treatment. trophils express high surface levels of PIG (phosphaietic precursors with G-CSF to neutrophils in vitro. 141 However, other explanations than influencing precursors by G-CSF tidylinositol glycan)-anchored Fc␥RIII which bind to the Fc part of multimeric IgG. Its expression increases during differfor the strong expression of the CD14 antigen on neutrophils are possible (see below). entiation of neutrophils with highest levels in mature cells. 134 Activation of neutrophils with certain agonists (eg fMLP) resulted in shedding of the Fc␥RIII from the cell surface and release of a soluble form of the receptor (sFc␥RIII) 135 which CD 11b:
The ␤ 2 integrin subfamily of adhesion molecules shares a common ␤-chain (CD18) and has three associated ␣-can be detected in human plasma. 136 In vitro, stimulation of neutrophils with G-CSF 27 or GMsubunits with it: CD11a (LFA-1), CD11b (Mo-1) and CD11c (p150,95 Administration of GM-CSF to patients with cancer resulted in an increased expression of the CD11b antigen on neutroexpression which include neutrophil immaturity, effects of G-CSF and GM-CSF on neutrophil precursors and shedding phils. 48, 73, 76, 144 This was also found in G-CSF-treated patients 48 ,111,117 using the mAb anti Mo-1 111,117 (Tables 1 and  induced by activation (see below). The latter topic was addressed in a study of Kerst et al 71 who showed that the con-3) and in healthy volunteers. 71 However, the latter results could not be confirmed by other groups using different anticentration of soluble Fc␥RIII in the plasma of volunteers treated with a single dose of G-CSF was increased for as long body clones 70,73 in neutrophils from patients after chemotherapy, healthy volunteers and patients with congenital neuas 10 days. A maximum level of sCD16 was observed after 6 days when neutrophil CD16 expression had already returned tropenias. 107 Kinetic studies have shown that the upregulation of the CD11b antigen is a very early event with a maximum to normal.
The meaning of the marked reduction of CD16 expression level of expression approximately 1 h after administration of G-CSF. 71, 111, 117 The enhanced CD11b expression proposed to for the functional abilities of these granulocytes has not been studied yet, but initiation of respiratory burst activity of Gbe closely associated with enhanced neutrophil adherence
might help to understand the initial neutropenia after G-CSF CSF-induced neutrophils with immune complexes binding to the Fc␥RIII revealed normal results (unpublished own administration (see above). observation).
Leukocyte adhesion molecule 1 (LAM-1, L-selectin):
The LAM-1 molecule belongs to the selectin family of adhesion CD14 and sCD14:
The receptor for LPS and LPS-binding protein (CD14) is a PIG-anchored membrane protein and is molecules and is rapidly shed from the cell surface after incubation of neutrophils with distinct activating agents (eg GMpredominantly expressed on monocytic cells and at low levels on neutrophils. 137 The neutrophil CD14 expression can be CSF, TNF␣) in vitro. 48, 59 Conflicting results have been reported on the influence of G-CSF on LAM-1 expression. Two groups upregulated by several agonists, eg IFN␥, 138 ,139 TNF␣, 140 G-CSF 73, 140 and GM-CSF 73, 140 (Table 1) . Administration of G-CSF found a significant downregulation of LAM-1 by G-CSF, 48, 60 whereas Griffin et al 59 described an unchanged expression to patients with acquired 70,73 and congenital neutropenias 107, 110 and to healthy volunteers 70,71 resulted in an after incubation of neutrophils with G-CSF. Interestingly, the affinity of LAM-1 for ligands (eg PPME) is markedly increased increased expression of the CD14 antigen on neutrophils, whereas GM-CSF did not alter the CD14 level. 73 Kinetic studafter short exposure of neutrophils to G-CSF. 146 LAM-1 has been shown to play an essential role in leukocyte rolling along ies could demonstrate maximal levels of expression 8-12 h after a single administration of G-CSF.
70, 71 Concentration of endothelium, the first step of the adhesion cascade. 142 An increased ligand binding affinity might contribute to the soluble CD14 was also increased in the plasma of G-CSFtreated healthy adults with a similar time pattern. 71 An enhanced adherence of G-CSF-induced neutrophils in vitro and in vivo. increased CD14 expression on G-CSF-induced neutrophils was observed, too, after differentiation of CD34 + hematopoAdministration of G-CSF 60 (and own unpublished ] i mobilization, membrane depolarization and increase in F-Actin constrongly diminished expression of LAM-1. However, other authors found an unaltered expression of the LAM-1 molecule tent. 108, 154 These defects in intracellular signalling might be related to the impaired O − 2 production and decreased chemoduring G-CSF and GM-CSF treatment 48, 147 (Tables 1 and 3) . Taken together, G-CSF and GM-CSF could induce an tactic activity also found in neutrophils from these patients.
108
The lack of functional studies prior to G-CSF treatment due to enhanced expression of the CD11b antigen and a diminished expression of the CD16 antigen and LAM-1 on neutrophils in severe neutropenia complicated the interpretation of the results. However, assessment of F-Actin, [Ca 2+ ] i mobilization vivo. An increased expression of the CD64 and CD14 antigens was found in G-CSF-induced neutrophils only.
and membrane depolarization revealed no abnormalities in G-CSF-induced neutrophils from patients with cancer.
154
Therefore, either a defect in signal transduction or the ongoing maturational arrest due to the underlying disease, but not GLeukocyte alkaline phosphatase activity (LAP)
CSF treatment are responsible for the functional impairments of neutrophils from patients with GSD IB and SCN. Leukocyte alkaline phosphatase is found in high levels in intracellular vesicles of neutrophils and is translocated to the plasma membrane after in vitro stimulation. 148 The activity of LAP increases during neutrophil maturation and can be used Morphology as a marker of maturity. 149 In vitro, G-CSF could induce LAPmRNA 150 and enhance LAP activity 151 in neutrophils. In addition, the decreased LAP score of neutrophils from patients Administration of G-CSF to patients and healthy volunteers resulted in some morphological immaturity of the induced with chronic myelogenous leukemia and myelodysplastic syndromes was enhanced by G-CSF in vitro. Administration of G-CSF to healthy volunteers and cancer patients resulted in a significant decrease of the neutrophil (Table 4) . Furthermore, a decreased nuclear lobulation showing nuclear immaturity 82,88,106 and hypogranularity 88 were LAP score lasting from 0.5 to 4 h after injection followed by a strong increase reaching a peak level of 48 h after injecpresent in G-CSF-induced neutrophils. Neutrophils with increased diameter were identified by conventional light tion 71, 72, 82 (Table 4 ). The initial decrease in the LAP score is probably caused by a sequestration of neutrophils with higher microscopy 88 and by an increased forward angle light scatter intensity in flow cytometric studies 154 in G-CSF-treated LAP activity from the bloodstream, 111 whereas cells with lower activity are left in the circulation. An alternative humans and rats 74 (Table 4) . Campbell et al 155 described the appearance of large, multilobulated and hypersegmented neuexplanation is the degranulation of LAP-containing secretory vesicles due to activation of the cells. trophils (macropolycytes) after G-CSF administration which were shown to be tetraploid. These cells were approximately In accordance with the in vitro results the reduced LAP scores in a patient with MDS recovered to normal values durtwice the size of normal neutrophils and represented mostly 3-5% of white cells. A nuclear hypersegmentation of periphing G-CSF therapy. 104, 152 The direct up-regulation of the LAP expression by G-CSF might explain that G-CSF-induced neueral blood neutrophils was also described in neutrophils from G-CSF-treated humans 88, 155 and rats. 74, 157 The administration trophils have increased LAP activity although they show some features of immaturity.
of GM-CSF also resulted in an altered neutrophil morphology including prominent granulation and vacuolization. 89 Taken together, the administration of G-CSF and GM-CSF could induce morphologic abnormalities of neutrophils, eg Mobilization of [Ca 2+ ] i , membrane depolarization, FActin content altered granularity and vacuolization. The hypersegmentation which can be observed in older neutrophils could be a result of delayed apoptosis seen after exposure of neutrophils to GNeutrophils from patients with GSD IB have been shown to be impaired in their ability to mobilize [Ca 2+ ] i in response to CSF in vitro (see above). Furthermore, increased diameter and altered cytoplasmatic structure was observed during G-CSF physiologic stimuli, eg fMLP.
153 Treatment of these patients with G-CSF resulted in a variable increase in the percentage treatment compatible with activation or immaturity of the cells. The latter might be caused by premature release of graof cells responding to fMLP stimulation.
11,109
Less severe functional deficits have been found in neutronulocytes from the bone marrow or direct effects of G-CSF and GM-CSF on precursors. phils from patients with severe congenital neutropenia after Giant neutrophils were present. 155 +, present; −, absent; same abbreviations as in Table 1 .
Possible mechanisms of G-CSF and GM-CSF action on
Neutrophilic dermatoses: Sweet's syndrome and bullous pyoderma gangraenosum neutrophil function in vivo Sweet's syndrome (acute febrile neutrophilic dermatosis) is Some explanations for the alterations in neutrophil phenotype characterized by pyrexia, neutrophilia, erythematous, painful and function have been suggested: (1) Activation (as indicated cutaneous plaques, dense dermal infiltrate of neutrophils and by the following findings, see above): G-CSF and GM-CSFa prompt response to corticosteroid therapy. 159, 160 Approxiinduced neutrophils were primed for an enhanced respiratory mately 10-15% of published cases occur in patients with canburst activity and showed enhanced adherence. These feacer. Several patients developing this syndrome during G-CSF tures could be found after exposure of neutrophils to these therapy have been described. 33, [161] [162] [163] [164] In each of these cytokines in vivo and in vitro and are therefore probably patients an underlying malignant disease was present and all caused by direct action of G-CSF and GM-CSF. (2) Induction received G-CSF in recommended dosages. The duration of Gof secondary cytokine production: Enhanced levels of IL-6 and CSF therapy ranged from 0 days to 1-2 months. Fukutoku et TNF␣ were found during GM-CSF therapy of neutropenic al 164 described three episodes of erythematous nodules in a patients 29, 30 which could in turn activate neutrophils. (3) Parpatient with aplastic anemia which could be induced by tial immaturity: Evidence arose especially from the morphoadministration of G-CSF and resolved rapidly after discontinulogical examinations, eg Dohle bodies and toxic granulation.
ing cytokine therapy. Interestingly, only doses of more than Furthermore, G-CSF and GM-CSF have been shown to act as 100 g of G-CSF per day caused the skin lesions, whereas release factors for neutrophils from the bone marrow includ-50 g were tolerated without any complications. ing cells which still have some degree of immaturity. In
Evidence that G-CSF might in fact be involved in the pathoaddition, some phenotypical characteristics of G-CSF-induced genesis of Sweet's syndrome is provided by one study in neutrophils were compatible with this hypothesis (eg which cytokine levels were measured during the clinical expression of Fc␥RI). (4) Effect on neutrophil precursors: This course of the disease. 165 Levels of G-CSF and IL-6 were view is supported by studies showing that differentiation of extremely high during the acute phase of disease, whereas CD34
+ cells with G-CSF in vitro resulted in Fc␥RI-positive levels of TNF␣, IFN␥ and IL-1␤ remained unchanged. neutrophils. G-CSF, but not GM-CSF shortened the maturation Additionally, in two patients occurrence of pyoderma gangtime of neutrophils in the bone marrow which might explain raenosum, characterized by dense neutrophilic infiltrates the differential effects of these cytokines on the Fc␥RI and without vasculitis or infection has been reported during treat-CD14 expression in vivo.
ment with G-CSF. 166, 167 In patients with primary neutrophil functional defects, eg GSD IB, G-CSF treatment was not able to restore completely the functional capacity of the induced neutrophils. This might be responsible for the better clinical response in patients with Leukocytoclastic vasculitis and interstitial lung disease SCN compared with GSD IB, the former showing mainly a maturational arrest in the bone marrow and only a moderate neutrophil functional deficit.
Leukocytoclastic vasculitis (LV) was observed in four patients receiving G-CSF therapy. 31, 32, 168, 169 In a recently published report of the Severe Chronic Neutropenia International Registry 3% of a total of 279 patients receiving long-term G-CSF treatment developed vasculitis. 170 In contrast to patients with neutrophilic dermatoses during G-CSF therapy, LV occurred Adverse effects of G-CSF possibly related to neutrophil activation mainly in patients with nonmalignant disorders, but also in recommended dosages 6-12 days after initiation of G-CSF. In three patients 32, 168, 169 two episodes of LV were induced by G-CSF, in the latter case complicated by renal involvement. Adverse reactions to G-CSF include bone pain, reversible abnormalities of liver function tests, elevations in serum uric Recently, several reports addressing the role of G-CSF in increasing pulmonary toxicity in combination with chemoacid levels and increase in lactate dehydrogenase activity.
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After GM-CSF administration more severe side-effects were therapy were published. Three studies described an enhanced incidence of drug-induced pneumonia (DIP) in patients observed, eg fluid retention, pleural and pericardial effusions and inflammation and a characteristic first dose reaction with treated with chemotherapy for lymphoma when G-CSF was given, [171] [172] [173] but only one of these reports compared their dyspnea, hypotension and tachycardia. Some of these sideeffects might be due to secondary cytokine production after results with a control group of patients not receiving G-CSF.
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Pooling data from two randomized trials Bastion et al 174 found GM-CSF administration, eg IL-6 and TNF␣. 29, 30 A detailed list of adverse effects can be found in the review of Lieschke et no increased incidence of DIP in patients with malignant lymphoma. Boogaerts et al 175 described three cases of ARDS al. 1, 158 In the following we will focus on the adverse effects of G-CSF because of its expanding clinical use.
occurring during G-CSF treatment of eight patients with druginduced agranulocytosis. Injury to pulmonary alveolar epiIn some patients neutrophilic dermatoses (Sweet's syndrome and pyoderma gangraenosum), leukocytoclastic vascuthelial cells is a prominent feature in a variety of lung diseases, eg the ARDS. Mechanisms involved in alveolar cell damage litis, interstitial pneumonia and ARDS have been observed during G-CSF treatment. These adverse effects might be assoinclude adherence of primed neutrophils via CD11b-dependent pathways and subsequent killing 176 as well as overprociated with the neutrophilia and neutrophil activation induced by G-CSF. It lowers the threshold for stimuli concentration duction of oxidative metabolites by cytotoxic drugs, eg bleomycin. 177 Since G-CSF has been shown to enhance some of required for initiation of respiratory burst activity or for the release of neutrophil enzymes, eg elastase, and might therethese functions (see above) it might well be involved in the cell injury of pulmonary vascular endothelial cells. fore result in tissue damage. 
The role of G-CSF and GM-CSF in infectious diseases
function could be partially restored by G-CSF or GM-CSF treatment. Therapy with G-CSF was in some cases associated with the G-CSF and GM-CSF can reduce the number of infectious episodes in patients with chemotherapy-induced and severe conoccurrence of side-effects such as leukocytoclastic vasculitis and neutrophilic dermatoses. G-CSF-induced and thereby genital neutropenia (see above) by shortening the time of neutropenia and increasing the neutrophil count. Moreover, by activated neutrophils might well cause or contribute to the tissue damage in these disorders. Although associated with enhancing neutrophil function and thereby their antimicrobial activity, G-CSF and GM-CSF could enhance the ability of neusome alterations in neutrophil phenotype and function, G-CSF treatment of children with SCN and other neutropenic trophils from neutropenic patients to fight infections.
Several groups have investigated the role of these cytokines disorders has resulted in a dramatic reduction of infectious episodes and an improvement of quality of life. in non-neutropenic animal model of infection, eg neonatal and intraabdominell sepsis (reviewed in Ref. 178 ). In most of the studies treatment with G-CSF significantly increased the References survival of these animals. However, the administration of GM-CSF to rats after the onset of sepsis decreased survival 179 and 1 Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor enhanced the endotoxin-induced lethality in a mouse and granulocyte-macrophage colony-stimulating factor (1). New Engl J Med 1992; 327: 28-35. model. 180 In two rat models G-CSF potentiated the lung dam-2 Demetri GD, Griffin JD. Granulocyte colony-stimulating factor age induced by ␣-naphthylthiourea and hydrochloric acid. However, in certain disorders (eg MDS) impaired neutrophil
